Wells Fargo & Company Cuts Autolus Therapeutics (NASDAQ:AUTL) Price Target to $6.00

Autolus Therapeutics (NASDAQ:AUTL) had its price objective lowered by Wells Fargo & Company from $8.00 to $6.00 in a research note published on Friday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $9.52.

Autolus Therapeutics Price Performance

Shares of AUTL stock opened at $1.70 on Friday. The firm has a market cap of $452.36 million, a P/E ratio of -1.40 and a beta of 2.07. Autolus Therapeutics has a 1-year low of $1.56 and a 1-year high of $6.60. The firm’s 50-day simple moving average is $2.02 and its 200-day simple moving average is $2.90.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.12. The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $2.98 million. Analysts expect that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Virtus ETF Advisers LLC raised its holdings in Autolus Therapeutics by 29.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company’s stock valued at $62,000 after buying an additional 6,081 shares during the period. Daiwa Securities Group Inc. grew its position in Autolus Therapeutics by 55.5% in the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock valued at $56,000 after acquiring an additional 8,479 shares in the last quarter. Bellevue Group AG grew its position in Autolus Therapeutics by 27.7% in the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after acquiring an additional 9,000 shares in the last quarter. State Street Corp grew its position in Autolus Therapeutics by 1.7% in the third quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after acquiring an additional 10,401 shares in the last quarter. Finally, Barclays PLC grew its position in Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company’s stock valued at $28,000 after acquiring an additional 10,866 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.